[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Editor's Correspondence
April 12, 2004

Discussing the Depression-Pain Dyad With Patients—Reply

Arch Intern Med. 2004;164(7):804-805. doi:10.1001/archinte.164.7.805-a

In reply

We find Dr Daniell's hypothesis about OPIAD and depression provocative. Whether the degree of androgen deficiency induced by opioid use is sufficient to cause clinical depression and, if so, in what proportion of patients are questions warranting further investigation. We are not familiar with published data showing that depression in opioid-treated patients is more refractory to antidepressant therapy, though Dr Daniell's experience could be corroborated in future trials. One would need to carefully control for other confounders, separate from opioid use, which might complicate depression response in patients with chronic pain. We would be cautious about advocating testosterone treatment for depression in patients receiving opioids until further trials with OPIAD have been conducted.

First Page Preview View Large
First page PDF preview
First page PDF preview
×